【摘要】 目的探讨食管癌患者血二氢嘧啶脱氢酶(dihydropyrimidine dehydrogen-ase,DPD)活性与一般临床资料、毒副作用及疗效的相关性。方法采用高效液相色谱法(high performanceliquidchromatog-raphy,HPLC)测定81例食管癌患者化疗前血DPD活性,行DLF方案化疗,同时观察化疗不良反应和疗效。结果血DPD活性在食管癌患者中呈正态分布。其与患者的一般临床资料无相关性,P>0.05;与5-FU致恶心呕吐、骨髓抑制、腹泻、口腔黏膜炎和疲劳等有相关性,P<0.05;与化疗疗效没有相关性,r=-0.81,P=0.11。结论血DPD活性与5-FU相关毒性呈负相关,与一般临床资料及化疗疗效无相关性。更多还原

【Abstract】 OBJECTIVE:To explore the relationship between DPD activity and the common clinical data, treatment response, adverse events in esophageal cancer patients. METHODS: The DPD activity in blood with esophageal cancer 81 patients was detected by high-performance liquid chromatography (HPLC) before chemotherapy. The patients with esophageal carcinoma received DLF regimen. Treatment response and adverse events in the patients were assessed. RESULTS: The DPD activity in blood was normally distributed in esophageal cancer patients. The DPD activity in blood had no correlation with common clinical data of the patients, P>0.05. The 5-FU associated toxicities had a negative relationship with DPD activity in blood, P<0.05. The DPD activity in blood had no relation with treatment response, r=-0.81, P=0.11. CONCLUSIONS: The DPD activity in blood negatively correlates with 5-FU associated toxicities. The DPD activity in blood does not correlates with common clinical data and treatment response in esophageal cancer patients.更多还原